

September 22, 2020

BSE Limited

Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip code: 532531 The National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex Bandra (E) Mumbai - 400 051 Scrip code: STAR

Dear Madam/ Sir,

Sub: Press Release

Please find attached Press Release issued by the Company titled:

"Strides receives USFDA approval for Butalbital, Acetaminophen, and Caffeine Tablets"

Thanks & Regards,

For Strides Pharma Science Limited,

Manjula Ramamurthy Company Secretary

Manjula R.

Encl. As above



Strides receives USFDA approval for Butalbital, Acetaminophen, and Caffeine Tablets

To be marketed by Strides Pharma Inc. in the US market

Bengaluru, September 22, 2020 – Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for *Butalbital, Acetaminophen, and Caffeine Tablets USP, 50 mg/325 mg/40 mg* from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Butalbital, Acetaminophen, and Caffeine Tablets USP, 50 mg/325 mg/40 mg, of Actavis Laboratories FL, Inc.

According to IQVIA MAT July 2020 data, the US market for Butalbital, Acetaminophen, and Caffeine Tablets USP, 50 mg/325 mg/40 mg is approximately US\$ 40 Mn. The product will be marketed by Strides Pharma Inc. in the US market.

The company has 126 cumulative ANDA filings with USFDA of which 91 ANDAs have been approved and 35 are pending approval.

About Butalbital, Acetaminophen, and Caffeine Tablets

Butalbital, acetaminophen, and caffeine tablets USP is indicated for the relief of the symptom complex of tension (or muscle contraction) headache.

About Strides

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy along with an institutional business to service donor-funded markets. The Company's global manufacturing sites are located in India (Chennai, Puducherry and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi) and the United States (Florida). The Company focusses on "difficult to manufacture" products that are sold in over 100 countries. Additional information is available at the Company's website at www.strides.com

For further information, please contact:

Strides

Badree Komandur

Executive Director – Finance & Group CFO +91 80 6784 0747

Investor Relations

Sandeep Baid: +91 80 6784 0791 Email: <u>Sandeep.baid@strides.com</u>

Corporate Communication

Usha lyer: +91 9987444106 Email: <u>usha.iyer@strides.com</u>

PR Consultancy

Fortuna PR

K Srinivas Reddy: +91 90005 27213

srinivas@fortunapr.com

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Regd. Office: 201, 'Devavrata', Sector - 17, Vashi,

Navi Mumbai - 400 703

Corp. Office: Strides House, Bannerghatta Road,

. Bengaluru – 560 076 K Priya: +91 95354 25418 priya@fortunapr.com